author-photo

Pallavi Shruti Mishra-Kalyani

Food and Drug Administration

14

Papers

203

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Project Switch: Lenalidomide and dexamethasone (Len-Dex) as a potential synthetic control arm (SCA) in relapsed or refractory multiple myeloma (rrMM).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)